RGEN Earnings & Financial Statements
Repligen Corporation
$172.51
-$1.37(-0.79%)
50
Overall
40
Value
58
Tech
52
Quality
Market Cap
$8.44B
Volume
899.60K
52W Range
$100.99 - $198.87
Target Price
$193.15
RGEN earnings and financial statements: Repligen Corporation's income statement, balance sheet and cash flow statement, annual and quarterly.
RGEN Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $738.26M | $634.44M | $632.36M | $801.54M | $670.53M |
| Cost of revenue | $352.01M | $359.79M | $353.92M | $345.83M | $279.28M |
| Operating income | $55.17M | -$35.11M | $47.70M | $224.67M | $167.25M |
| EBITDA | $197.50M | $95.85M | $130.21M | $273.10M | $203.27M |
| Net income | $48.89M | -$25.51M | $35.60M | $185.96M | $128.29M |
| EPS (diluted) | $0.86 | $-0.46 | $0.74 | $3.24 | $2.24 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $2.95B | $2.83B | $2.83B | $2.52B | $2.36B |
| Total liabilities | $843.57M | $856.95M | $866.34M | $613.96M | $608.29M |
| Shareholders’ equity | $2.11B | $1.97B | $1.96B | $1.91B | $1.75B |
| Cash and equivalents | $566.02M | $757.36M | $751.32M | $523.46M | $603.81M |
| Long-term debt | $668.39M | $671.14M | $636.72M | $131.39M | $102.49M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $117.42M | $175.39M | $113.92M | $172.08M | $119.02M |
| Capital expenditure | -$25.49M | -$32.91M | -$38.99M | -$133.35M | -$71.28M |
| Free cash flow | $91.69M | $142.49M | $74.93M | $38.74M | $47.74M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RGEN | $172.51 | -0.8% | 899.60K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |